2025-06-05-Jefferies-节奏制药公司（RYTM）_JEF医疗保健会议+团体晚宴_下半年非常有趣的布局_7页_102kb

Rhythm Pharmaceuticals (RYTM) Summary

Core Content Overview

This document provides an analysis of Rhythm Pharmaceuticals (RYTM), focusing on its H2 2025 strategic developments and investment outlook. The report highlights key clinical data, market potential, and the analysts' confidence in the company's pipeline. It also includes a Buy rating with a price target of $80.00, representing a +24% increase from the current price of $64.40. The company's market cap is $4.1B, and the report notes the importance of reimbursement dynamics, data updates, and pipeline de-risking for future valuation and stock performance.

Key Highlights

1. Clinical Pipeline and Data Expectations

• Phase II Oral HO Data (Q3 2025):

  • Management expects >10% BMI reduction.
  • Data will be presented on an apples-to-apples basis compared to setmelanotide.
  • Focus will shift from mean values to individual-level data, including waterfall plots.
  • Safety data is blinded, and hyperpigmentation is expected to be significantly lower than with setmelanotide, though not necessarily eliminated.

• Phase IB Weekly SubQ HO Data (by YE:25):

  • Data is on track for H2:25.
  • Management is more confident in the weekly subQ due to internal development and alignment with setmelanotide.
  • GI side effects are observed, which are expected and indicate target engagement.

• Setmelanotide PWS Data (by YE:25):

  • A major call option for RYTM.
  • Higher dose (5mg vs 2.5mg) and longer trial duration (6mos vs 4-8w) aim to improve PoC (Proof of Concept) for weight loss.
  • Management believes tolerability is high, with anecdotal feedback supporting this.
  • The goal is to achieve at least 5% weight loss, which would differentiate RYTM from competitors.

2. Market and Investment Outlook

• HO Market Potential:

  • Incremental data will be presented at ENDO 2025.
  • Management is shifting focus from revenue expectations to patient starts during the initial launch phase.
  • Reimbursement delays are a key factor, similar to DCCR for PWS and Crenessity for CAH.
  • 2026 approval is expected, but consensus revenue estimates may be too aggressive, with $1B projected for 2030 HO, which could be revised downward.

• Investment Recommendation:

  • Buy rating with a price target of $80.00.
  • The DCF-based valuation method is used.
  • The report emphasizes de-risking of the pipeline and LCM (License, Collaboration, Merger) as potential scenarios for M&A activity.

Key Information and Strategic Points

• Pipeline De-Risking:

  • The oral and weekly subQ data are critical for extending the franchise beyond the 2032-34 LOE (License of Expectation).
  • OLE (Open-Label Extension) will follow the Phase II trial, offering longer-term BMI trend analysis.

• Differentiation Strategy:

  • RYTM aims to differentiate its product from competing therapies by showcasing weight loss benefits in PWS.
  • The weekly subQ is seen as a more selective option for MC4R (Melanocortin 4 Receptor) targeting.

• Risks and Considerations:

  • Clinical risks remain, especially with the PWS trial.
  • Regulatory and commercial risks are highlighted, particularly around reimbursement timelines.
  • The stock is not currently in the portfolio due to lack of weight loss data.

Analysts and Contact Information

• Analysts:

  • Dennis Ding – Equity Analyst
  • Anthea Li – Equity Associate
  • Georgia Bank – Equity Associate

• Contact Details:

  • Dennis Ding: (212) 336-7325 | dding@jefferies.com
  • Anthea Li: (212) 336-6681 | ali9@jefferies.com
  • Georgia Bank: +1 (212) 778-8476 | gbank@jefferies.com

Summary of Valuation and Investment Themes

• Valuation Methodology:

  • Includes market cap, DCF, growth/value, volatility, and expected total return.
  • The price target is based on market risk, growth rate, revenue stream, and differentiated analysis.

• Investment Themes:

  • Rare genetic obesity treatment.
  • Differentiated weight loss in PWS.
  • Pipeline de-risking and M&A potential.
  • Reimbursement dynamics influencing launch and revenue expectations.

Key Financial Metrics

• Current Price: $64.40
• Price Target: $80.00 (+24%)
• 52-Week High-Low: $68.58 - $38.82
• Market Cap: $4.1B
• Float: 90.5%
• Average Daily Volume (ADV): $40.44M

Conclusion

The report is optimistic about RYTM's future with strong data expectations in H2:25, especially for HO (Hormone-Related Obesity) and PWS (Prader-Willi Syndrome). The Buy rating reflects high analyst conviction, supported by pipeline progress, differentiated benefits, and potential M&A. Investors are advised to monitor the reimbursement timeline, safety data, and long-term BMI trends as key factors in the company's performance.